Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide and SU5416 in Metastatic Melanoma
NCT00017316Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2001
- Primary completion
- Sep 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide, semaxanib in melanoma, sponsored by National Cancer Institute. Started Mar 2001; status: completed.
02
Drugs
thalidomidesemaxanib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00017316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00017316.